Fenofibrate-Induced Rhabdomyolysis in a Patient With Stage 4 Chronic Renal Failure Due To Diabetes Mellitus
dc.authorid | Reha, Erkoc/0009-0001-7230-8843 | |
dc.authorscopusid | 13105952900 | |
dc.authorscopusid | 54382862800 | |
dc.authorscopusid | 49461096800 | |
dc.authorscopusid | 36165464000 | |
dc.authorscopusid | 10242147700 | |
dc.authorscopusid | 8409430500 | |
dc.authorwosid | Turan Canbaz, Esra/Kxs-1505-2024 | |
dc.authorwosid | Begenik, Huseyin/Lkl-8263-2024 | |
dc.contributor.author | Soyoral, Yasemin Usul | |
dc.contributor.author | Canbaz, Esra Turan | |
dc.contributor.author | Erdur, Mehmet Fatih | |
dc.contributor.author | Emre, Habib | |
dc.contributor.author | Begenik, Huseyin | |
dc.contributor.author | Erkoc, Reha | |
dc.date.accessioned | 2025-05-10T17:47:58Z | |
dc.date.available | 2025-05-10T17:47:58Z | |
dc.date.issued | 2012 | |
dc.department | T.C. Van Yüzüncü Yıl Üniversitesi | en_US |
dc.department-temp | [Soyoral, Yasemin Usul; Erdur, Mehmet Fatih; Emre, Habib; Begenik, Huseyin] Yuzuncu Yil Univ, Dept Nephrol, Van, Turkey; [Canbaz, Esra Turan] Yuzuncu Yil Univ, Dept Internal Med, Van, Turkey; [Erkoc, Reha] Univ Bezmi Alem Vakif, Dept Nephrol, Istanbul, Turkey | en_US |
dc.description | Reha, Erkoc/0009-0001-7230-8843 | en_US |
dc.description.abstract | Rhabdomyolysis is defined as a pathological condition of skeletal muscle cell damage leading to the release of toxic intracellular components into the circulation. Several factors may lead to rhabdomyolysis. Fenofibrate is a fibric acid derivative agent that is used in the treatment of hyperlipidaemia. Although several case reports of rhabdomyolysis have been reported due to the combination of statin and fenofibrate, fenofibrate alone rarely causes rhabdomyolysis. When administering fenofibrate in chronic renal failure, dose should be adjusted. Here, we report a case with fenofibrate-induced rhabdomyolysis in a patient with chronic renal failure. | en_US |
dc.description.woscitationindex | Science Citation Index Expanded | |
dc.identifier.endpage | 851 | en_US |
dc.identifier.issn | 0030-9982 | |
dc.identifier.issue | 8 | en_US |
dc.identifier.pmid | 23862266 | |
dc.identifier.scopus | 2-s2.0-84880792346 | |
dc.identifier.scopusquality | Q3 | |
dc.identifier.startpage | 849 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.14720/16926 | |
dc.identifier.volume | 62 | en_US |
dc.identifier.wos | WOS:000306049600026 | |
dc.identifier.wosquality | Q4 | |
dc.language.iso | en | en_US |
dc.publisher | Pakistan Medical Assoc | en_US |
dc.relation.publicationcategory | Diğer | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Fenofibrate | en_US |
dc.subject | Rhabdomyolysis | en_US |
dc.subject | Chronic Renal Failure | en_US |
dc.title | Fenofibrate-Induced Rhabdomyolysis in a Patient With Stage 4 Chronic Renal Failure Due To Diabetes Mellitus | en_US |
dc.type | Editorial | en_US |